Literature DB >> 11401107

Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients.

Y Krupova, M Mistrik, E Bojtarova, D Sejnova, I Ilavska, V Krcmery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11401107     DOI： 10.1007/s005200000194

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

1.  Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.

Authors:  A H Groll; C E Gonzalez; N Giri; K Kligys; W Love; J Peter; E Feuerstein; J Bacher; S C Piscitelli; T J Walsh
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

2.  Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.

Authors:  M H White; E J Anaissie; S Kusne; J R Wingard; J W Hiemenz; A Cantor; M Gurwith; C Du Mond; R D Mamelok; R A Bowden
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

3.  Amphotericin B lipid complex in pediatric patients with invasive fungal infections.

Authors:  T J Walsh; N L Seibel; C Arndt; R E Harris; M J Dinubile; A Reboli; J Hiemenz; S J Chanock
Journal:  Pediatr Infect Dis J       Date:  1999-08       Impact factor: 2.129

4.  Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.

Authors:  T L Wallace; V Paetznick; P A Cossum; G Lopez-Berestein; J H Rex; E Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

Authors:  T J Walsh; J W Hiemenz; N L Seibel; J R Perfect; G Horwith; L Lee; J L Silber; M J DiNubile; A Reboli; E Bow; J Lister; E J Anaissie
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079
  5 in total
  2 in total

1.  Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism.

Authors:  Raymund R Razonable; Martin Henault; Harold L Watson; Carlos V Paya
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

Authors:  Fritz Offner; Vladimir Krcmery; Marc Boogaerts; Chantal Doyen; Dan Engelhard; Patricia Ribaud; Catherine Cordonnier; Ben de Pauw; Simon Durrant; Jean-Pierre Marie; Philippe Moreau; Harry Guiot; George Samonis; Richard Sylvester; Raoul Herbrecht
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.